Vertex Pharmaceuticals (VRTX) Invested Capital (2009 - 2026)

Vertex Pharmaceuticals' Invested Capital history runs 18 years deep, the most recent figure standing at $19.4 billion for Q1 2026.

• In Q1 2026, Invested Capital rose 17.37% year-over-year to $19.4 billion; the TTM figure through Mar 2026 stood at $19.4 billion (up 17.37% YoY), while the FY2025 annual figure was $18.7 billion, up 12.94% from the prior year.
• Invested Capital was $19.4 billion for Q1 2026 at Vertex Pharmaceuticals, up from $18.7 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $19.4 billion in Q1 2026 to a low of $10.9 billion in Q1 2022.
• Historically, Invested Capital has averaged $15.8 billion across 5 years, with a median of $16.5 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Invested Capital jumped 36.71% in 2022, then retreated 11.05% in 2025.
• A 5-year view of Invested Capital shows it stood at $14.4 billion in 2022, then increased by 25.19% to $18.0 billion in 2023, then dropped by 8.22% to $16.5 billion in 2024, then climbed by 12.94% to $18.7 billion in 2025, then grew by 3.73% to $19.4 billion in 2026.
• The last three Invested Capital figures came in at $19.4 billion (Q1 2026), $18.7 billion (Q4 2025), and $17.3 billion (Q3 2025), per Business Quant data.